Regulatory FDA seeks permanent future for rare pediatric priority review vouchers Pharmaceutical TechnologyThe rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.RegulatoryRare DiseaseRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Technology The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability. RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Syneron raises $150m for macrocyclics, and other financingsNext: Jeito Capital secures over $1.2bn for new biopharma investments Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
